Orion OyjORINF +4.81%100 Pretax Margin % is 27.15% as of Mar. 2026, which is 3% above its 10-year median of 26.30. GuruFocus rates ORINF with a GF Score™ of 100/100 and a GF Value™ of $86.78. The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, Orion Oyj ranks better than 93.61% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Orion Oyj's Pre-Tax Income for the
three
months ended in Mar. 2026 was $131 Mil. Orion Oyj's Revenue for the
three
months ended in Mar. 2026 was $483 Mil. Therefore, Orion Oyj's pretax margin for the quarter that ended in Mar. 2026 was 27.15%.
The historical rank and industry rank for Orion Oyj's Pretax Margin % or its related term are showing as below:
ORINF'
s Pretax Margin % Range Over the Past 10 Years
Min: 22.86 Med: 26.3 Max: 34.01
Current: 34.01
ORINF's Pretax Margin % is ranked better than 93.61% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs ORINF: 34.01
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Orion Oyj Pretax Margin % Related Terms
Orion Oyj Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Orion Oyj's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORINF vs LLY, JNJ, ABBV: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, Orion Oyj's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Orion Oyj's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Oyj (ORINF) has a Pretax Margin % of 27.15% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Orion Oyj and its competitors. This is near median its historical median of 26.30. Over the past decade, Orion Oyj's Pretax Margin % has ranged from 22.86 to 34.01. According to the industry distribution chart, Orion Oyj ranks #61 out of 955 companies in the Drug Manufacturers industry, placing it in the top 6.4%.
Is Orion Oyj's Pretax Margin % too high?
Orion Oyj's current Pretax Margin % of 27.15% is near median its 10-year median of 26.30. Over the past 10 years, this metric has ranged from a low of 22.86 to a high of 34.01. The Drug Manufacturers industry median Pretax Margin % is 7.28. Orion Oyj's value of 27.15% is 272.9% above this industry median. Based on the distribution chart, Orion Oyj ranks #61 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orion Oyj has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's Pretax Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #61 out of 955 companies for Pretax Margin %. This places Orion Oyj in the top 6% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Orion Oyj's value of 27.15% is 272.9% above this benchmark. Historically, Orion Oyj's own Pretax Margin % has ranged from 22.86 to 34.01 over the past decade. While the company's 10-year median is 26.30 vs. the industry median of 7.28, Orion Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Oyj's current Pretax Margin % of 27.15% is 272.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Orion Oyj and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Oyj's current Pretax Margin % is 27.15%, which is near median its own 10-year median of 26.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Orion Oyj (ORINF) has a current Pretax Margin % of 27.15%. The stock's GF Value™ is $86.78, compared to a current price of $82.75 — trading 4.6% below its estimated fair value. The current Pretax Margin % is 27.15%, which is near median its 10-year median of 26.30 and 272.9% above the Drug Manufacturers industry median of 7.28. Orion Oyj's overall GF Score™ is 100/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Orion Oyj (ORINF), the current Pretax Margin % is 27.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (ORINF) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be undervalued.
The current stock price of $82.75 is trading 4.6% below its estimated GF Value™ of $86.78.
Key valuation signals for ORINF:
Pretax Margin %: 27.15% (near median its 10-year median of 26.30)
GF Value™: $86.78 vs. price of $82.75 (4.6% below fair value)
Industry Position: 272.9% above the Drug Manufacturers median (#61 of 955)
No single metric tells the full story. See the ORINF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
100GF Score
Get the complete analysis for ORINF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORINF has been successfully added to your 
